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Abstract
Background: The elderly patients affected by candidemia are growing in proportion to inpatients, but available
data are limited. We aimed to determine the epidemiology, antifungal management and clinical risk factors of
death in the elderly population with candidemia in China.
Methods: This retrospective study included 63 elderly (≥65 years) and 84 younger patients (16–60 years) at 4
tertiary hospitals. Multivariable logistic regression model was used to identify independent risk factors of death in
elderly patients.
Results: The distribution of Candida species did not differ between elderly and younger patients (p >0.05).
Resistance to fluconazole and voriconazole for non-Candida albicans species in elderly patients was approximately
double that in younger patients. Host-related risk factors (e.g., underlying solid tumour, diabetes mellitus and
chronic renal failure) and hospital-related factors (e.g., prior stay in an intensive care unit, mechanical ventilation,
central vascular and urethral catheters placement) were identified more common in elderly patients. Elderly patients
less often received triazoles and were less likely to receive antifungal therapies mostly because elderly or their
guardians quit antifungal therapies. APACHE II scores and 30-day mortality were higher for elderly than younger
patients (31.7% vs. 16.7%, p =0.032). For elderly patients, antifungal therapy administered before microbiological
documentation was the only protective factor for death, whereas absence of antifungal therapies, receipt of
mechanical ventilation and APACHE II score ≥20 were independent predictors of death.
Conclusions: Elderly patients with candidemia had poor prognoses characterized by certain host and hospital-related risk
factors and special pathogen resistance features. More awareness of the burden of this disease is required, and the absence
of antifungal therapies should be avoided to improve the prognoses of elderly patients with this severe infection.
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Background
Candidemia has emerged as an important nosocomial
infection associated with significant morbidity and mor-
tality [1-3]. It is the fourth most common nosocomial
bloodstream infection in the United States and the sev-
enth in Europe [4,5]. It prolongs hospital stays and in-
creases the costs associated with patient management
[6]. The epidemiology of candidemia has been studied
extensively worldwide, and data are available from a
large series of laboratory-based and population-based
surveillance studies, as well as studies focusing on spe-
cific patient populations such as neonates and those with
cancer, undergoing surgery, and staying in intensive care
units (ICUs) patients [7-11].
The elderly population is large and is growing in propor-
tion to the general hospitalized population. Because of co-
morbidities, aging and age-associated physiological changes,
increased rates of oropharyngeal colonization with Candida
species, and concomitant drug use, elderly patients are more
vulnerable to Candida infections [12,13]. The features of the
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pathogen, risk factors and severity of candidemia in elderly
patients may differ from that in younger adults and might
be associated with worse prognosis [14]. Moreover, physi-
cians may choose different antifungal management for
elderly and younger patients, depending on patient’ com-
pliance, individual experiences and different guidelines
[15]. However, available data for elderly patients with can-
didemia are limited [16,17].
Here, we hypothesized that candidemia in elderly patients
would present several peculiarities in epidemiology, clinical
risk factors for death and antifungal management. To
characterize these peculiarities, we evaluated a database of
patients with candidemia from 4 multicentre, retrospective
surveillance studies coordinated by our group, and com-
pared the above indicators in elderly versus younger pa-
tients. Furthermore, to improve the clinical management
and outcome of elderly patients, we used multiple logistic
analyses to identify the risk factors for death.
Methods
Study design and patient selection
We performed a multicentre retrospective study of candi-
demia in 4 tertiary general hospitals in Shandong, China:
Qilu Hospital of Shandong University (Jinan, 2000 beds),
Qianfoshan Hospital affiliated with Shandong University
(Jinan, 1500 beds), Jinan Center Hospital affiliated with
Shandong University (Jinan, 1000 beds), and Liaocheng
People’s Hospital affiliated with Taishan Medical College
(Liaocheng, 2000 beds). The study was conducted from
June 2008 to June 2010. We included patients ≥16 years
who had hospital acquired candidemia, which was defined
as at least one positive blood culture for Candida species in
patients hospitalized for more than 48 hrs with clinical
signs and symptoms of sepsis [18]. Elderly patients were de-
fined as the patients 65 years of age or older, whereas pa-
tients with the age between 16 and 60 were defined as
younger patients. All episodes of candidemia were identi-
fied via the laboratory computer system. For patients with
multiple candidemic episodes, only the first episode was in-
cluded. Patients with candidemia caused simultaneously by
different species of Candida were excluded. The study was
approved by the Ethics Committee of Qilu Hospital of
Shandong University and was carried out according to the
ethical standards set forth in the Declaration of Helsinki of
1964.
Data collection
Trained study team members collected demographic
and clinical data by chart review. Demographic and
microbiological data, underlying diseases, predisposing
factors, laboratory data, concurrent infections, antifungal
agents exposure and outcome were recorded on stan-
dardized case report forms.
Candida species were identified by use of the VITEK-32
system (BioMerieux Vitek, St. Louis, MO, USA). We used
the recently updated species-specific antifungal drug sus-
ceptibility thresholds for fluconazole, voriconazole and cas-
pofungin by the Clinical and Laboratory Standards Institute
(CLSI) [19-21]. Isolates of C. krusei were considered intrin-
sically resistant to fluconazole. For voriconazole, isolates of
C. glabrata and C. krusei isolates with minimal inhibitory
concentration (MIC) of ≥2 μg/ml were considered resistant.
Predisposing factors (including immunosuppressive drugs
and severe hypoalbuminemia) and underlying diseases
(including solid organ tumour, hematologic malignancy,
neutropenia, diabetes mellitus and chronic renal failure)
were recorded as host-related risk factors [22]. Other pre-
disposing factors, including surgeries, abdominal surgical
operations, ICU stay ≥5 days, multiple blood product
transfusion, parenteral nutrition, receipt of mechanical
ventilation, placement of central venous catheter (CVC)
or urethral catheter, and prior antibacterial exposure were
recorded as hospital-related risk factors [22]. All predis-
posing factors had to occur within 30 days before the on-
set of candidemia. CVC-related candidemia required the
isolation of the same Candida spp. from both blood and
catheter tip.
The severity of the initial presentation of candidemia
was assessed by the Acute Physiology and Chronic
Health Evaluation (APACHE) II score [23]. Because of
the specific purpose of the study, we additionally re-
ported an age-adjusted APACHE II score in which
points attributed to older age were subtracted from the
total score. We recorded the antifungal agents used for
more than 2 days within 2 weeks before and 2 weeks
after the microbiological documentation of candidemia.
Neutropenia was defined as absolute neutrophil count
<0.5 × 109/l. Severe hypoalbuminemia was defined as serum
albumin levels <23 g/L. Immunosuppressive drugs received
included glucocorticoids (≥20 mg/day of prednisone or
equivalent doses of other corticosteroids for >1 week),
chemotherapy drugs or other immunosuppressive agents.
Multiple blood product transfusion was defined as transfu-
sion of ≥6 units consisting of at least 2 units of erythrocytes
and 2 units of fresh frozen plasma. Septic shock was de-
fined as systolic blood pressure <90 mmHg, diastolic blood
pressure <60 mmHg, or fluid/inotrope required to maintain
blood pressure above these levels. Concurrent bloodstream
infections were defined as an isolation of a positive culture
for bacterium in patients with signs or symptoms of
infection that occurred within 2 weeks of the onset of
candidemia.
Statistical analyses
The data for categorical variables are expressed as percent-
ages and continuous variables as mean ± SD or median
with inter-quartile range (IQR). Chi-square or Fisher’s exact
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test (two-tailed) was used to compare categorical variables
and unpaired Student’s t test or Mann–Whitney U test to
compare continuous variables. Multivariable, backwards,
stepwise, logistic regression analyses was used to identify
independent risk factors associated with day-30 mortality of
elderly patients with candidemia. Variables with p ≤0.10 on
univariate analyses were entered into the multivariable
model. Statistical analyses involved use of SPSS v15.0 for




We detected 154 cases of candidemia and excluded 7
cases of polyfungal candidemia, leaving 147 cases in 147
patients for analyses (mean age 55.0 ± 12.4 years; 110
men): 63 elderly patients (42.9%) and 84 (57.1%) younger
patients. The 2 groups did not differ in male sex and
length of stay (Table 1). The elderly patients were more
often admitted to ICUs than younger patients (49.2% vs.
23.8%; p =0.001) and were less often admitted to medical
wards (22.2% vs. 38.1%; p =0.040).
Microbiology of Candida species
The Candida species isolated were as follows: 27 C. albi-
cans (42.9%), 16 C. tropicalis (25.4%), 9 C. parapsilosis
(14.3%), 7 C. glabrata (11.1%), 3 C. krusei (4.8%) and 1 C.
famata (1.6%) in the elderly patients; 31 C. albicans
(36.9%), 19 C. tropicalis (22.6%), 17 C. parapsilosis (20.2%),
9 C. glabrata (10.7%), 6 C. krusei (7.1%), and C. rugosa and
C. guilliermondii (n = 1 each; 1.2%) in younger patients
(Table 2). The distribution of Candida species did not differ
between elderly and younger patients (p >0.05).
Table 1 Demographics and clinical risk factors of the elderly and younger patients with candidemia
Characteristics Elderly patients (≥65 years, n =63) Younger patients (16–60 years, n =84) p value
Age (years)a 75.4 ± 12.7 39.6 ± 11.2 <0.001
Male sex 51 (81.0) 59 (70.2) 0.139
Length of staya 45.3 ± 32.8 39.2 ± 30.9 0.251
Hospital settings
ICUs 31 (49.2) 20 (23.8) 0.001
Medical wards 14 (22.2) 32 (38.1) 0.040
Surgical wards 12 (19.0) 25 (29.8) 0.139
Others 6 (9.5) 7 (8.3) 0.801
Host-related risk factors
Solid tumour 15 (23.8) 5 (6.0) 0.002
Haematological malignancyb 3 (4.8) 14 (16.7) 0.026
Neutropenia 5 (7.9) 20 (23.8) 0.011
Diabetes mellitus 24 (38.1) 8 (9.5) 0.001
Chronic renal failure 18 (28.6) 7 (8.3) 0.001
Prior immunosuppressive drugs 16 (25.4) 25 (29.8) 0.559
Severe hypoalbuminemia 13 (20.6) 10 (11.9) 0.149
Hospital-related risk factors
Surgery 14 (22.2) 29 (34.5) 0.105
Abdominal surgical operations 9 (14.3) 14 (16.7) 0.694
ICU stay ≥5 days 19 (30.2) 6 (7.1) 0.001
Multiple blood product transfusion 8 (12.7) 16 (19.0) 0.303
Parental nutrition 20 (31.7) 16 (19.0) 0.076
Receipt of mechanical ventilation 27 (42.9) 20 (23.8) 0.014
CVC placement 32 (50.8) 26 (31.0) 0.015
Urethral catheter placement 34 (54.0) 29 (34.5) 0.018
Prior antibacterial exposureb 63 (100.0) 82 (97.6) 0.607
≥ 3 kinds of prior antibacterial drugs 29 (46.0) 34 (40.5) 0.501
Data are n (%) or mean ± SD.
ICU, intensive care unit; CVC, central venous catheter.
aTwo-independent samples t-test; bFisher’s exact test; Unspecified: chi-square test.
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We found resistance to fluconazole, voriconazole and cas-
pofungin for C. albicans in 1/27 (3.7%), 1/27 (3.7%), 0/27
(0%) in elderly patients and 1/31 (3.2%), 0/31 (0%), 0/31
(0%) in younger patients, respectively (Table 2). In elderly
patients, the resistance to fluconazole and voriconazole of
non-C. albicans species was approximate double that of
younger patients [30.6% (11 of 36) vs. 15.1% (8 of 53), 8.3%
(3 of 36) vs. 3.8% (2 of 53), respectively]; however, all the iso-
lates in younger and elderly patients were susceptible to
caspofungin.
Clinical risk factors
Elderly patients more often presented with solid tumour
(23.8% vs. 6.0%; p =0.002), diabetes mellitus (38.1% vs.
9.5%; p =0.001), or chronic renal failure (28.6% vs. 8.3%;
p =0.001), and less often with haematological malignancy
(16.7% vs. 4.8%; p =0.026) and neutropenia (23.8% vs. 7.9%;
p =0.011). In addition, elderly patients more often under-
went procedures defined as hospital-related risk factors, in-
cluding prior ICU stay ≥5 days (30.2% vs. 7.1%; p =0.001),
mechanical ventilation (42.9% vs. 23.8%; p =0.014), CVC
(50.8% vs. 31.0%; p =0.015) and urethral catheter placement
(54.0% vs. 34.5%; p =0.018) (Table 1). The incidence of the
other risk factors, including prior immunosuppressive
drugs and severe hypoalbuminemia, abdominal surgical
operations, multiple blood product transfusion, parental
nutrition and prior antibacterial exposure, did not differ be-
tween the two groups.
Antifungal agent exposure
The 2 age groups did not differ in the selection of antifungal
agents before or after the identification of Candida species
Table 2 Candida species distribution and resistance to antifungal agents isolated from patients
Candida species Elderly patients (≥65 years, n =63) Younger patients (16–60 years, n =84)
Candida albicans 27/63 (42.9) 31/84 (36.9)
Fluconazole 1/27 (3.7) 1/31 (3.2)
Voriconazole 1/27 (3.7) 0/31 (0)
Caspofungin 0/27 (0) 0/31 (0)
Non-C. albicans species 36/63 (57.1) 53/84 (63.1)
Fluconazole 11/36 (30.6) 8/53 (15.1)
Voriconazole 3/36 (8.3) 2/53 (3.8)
Caspofungin 0/36 (0) 0/53 (0)
Candida tropicalis 16/63 (25.4) 19/84 (22.6)
Fluconazole 4/16 (25.0) 1/19 (5.3)
Voriconazole 2/16 (12.5) 1/19 (5.3)
Caspofungin 0/16 (0) 0/19 (0)
Candida parapsilosis 9/63 (14.3) 17/84 (20.2)
Fluconazole 2/9 (22.2) 1/17 (5.9)
Voriconazole 0/9 (0.0) 0/17 (0)
Caspofungin 0/9 (0) 0/17 (0)
Candida glabrata 7/63 (11.1) 9/84 (10.7)
Fluconazole 2/7 (28.6) 0/9 (0)
Voriconazole 1/7 (14.3) 0/9 (0)
Caspofungin 0/7 (0) 0/9 (0)
Candida kruseia 3/63 (4.8) 6/84 (7.1)
Fluconazole 3/3 (100.0) 6/6 (100.0)
Voriconazole 0/3 (0) 1/6 (16.7%)
Caspofungin 0/3 (0) 0/6 (0)
Othera 1/63 (1.6)* 2/84 (2.4) †
Fluconazole 0/1 (0) 0/2 (0)
Voriconazole 0/1 (0) 0/2 (0)
Caspofungin 0/1 (0) 0/2 (0)
Data are n (%).
*including 1 C. famat.
†including 1 C. rugosa and 1 C. guilliermondii.
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(all p >0.05) (Table 3). Overall, elderly patients were less
often administered triazoles (57.1% vs. 78.6%; p =0.005) and
were more often lacking antifungal therapies (25.4% vs.
11.9%; p =0.034) compared with younger patients (Table 3).
The possible reasons for the absence of antifungal therapy
in the elderly were determined from the medical records: 11
patients or their guardians decided to quit antifungal ther-
apy, mainly because of hopelessness in the recovery, high
hospitalization expenses, or non-coverage of antifungal
agents by medical insurance; 2 patients died before micro-
biologicy documentation of Candida in the bloodstream;
and 3 patients with undetermined reasons.
Laboratory data, outcomes and risk factors for death in
elderly patients
Compared with younger patients, elderly patients were
sicker, as shown by significant higher serum creatinine
level (112.0 ± 95.3 vs. 82.4 ± 65.6, p =0.027) and blood
sugar level (9.3 ± 5.1 vs. 6.7 ± 2.8, p =0.001) as well as sig-
nificantly higher APACHE II score (20.3 ± 8.1 vs. 14.6 ±
7.3; p =0.001) (Table 4). However, no significant differences
were noted in age-adjusted APACHE II scores (16.2 ± 7.7
vs. 13.9 ± 7.1; p =0.063). The elderly patients had
significantly higher 30-day mortality rates (31.7% vs. 16.7%,
p =0.032).
On univariate analyses, compared with non-survivors,
survivors showed higher, although not significantly propor-
tion of prophylactic and empiric treatment (all p >0.10)
(Table 5); the rate of CVC removal was higher for survivors
than non- survivors (p <0.10) and was included in the mul-
tivariable regression analyses. On multivariable analyses,
antifungal therapy administered before microbiological
documentation was the only protective factor for death
(odds ratio [OR]0.8, 95% confidence interval [95% CI] 0.7–
0.9, p =0.046). Independent predictors of death were
absence of antifungal therapies (OR 2.1; 95% CI 1.2–23.8;
p =0.039), receipt of mechanical ventilation (OR 3.5; 95%
CI 1.6–12.4; p =0.042) and APACHE II score ≥20 (OR 4.0;
95% CI 2.5–8.6; p =0.018).
Discussion
A major strength of this study is that our data are
representative of 4 centres and included patients from differ-
ent hospital settings in China. The resistance to fluconazole
and vorizonazole of non-C. albicans species in elderly pa-
tients being double that in younger patients should be ad-
dressed when applying empirical or prophylactic antifungal
Table 3 Antifungal therapy started before and after microbiological documentation of Candida in the bloodstream
Characteristics Elderly patients
(≥65 years, n =63)
Younger patients
(16–60 years, n =84)
p value
Antifungal therapy administered before microbiological documentation 22 (34.9%) 47 (56.0%) 0.011
Treatment method
Prophylactic treatment 7 (11.1%) 17 (20.2%) 0.138
Empiric treatment 12 (19.0%) 23 (27.4%) 0.240
Undetermineda 3 (4.8%) 7 (8.3%) 0.603
Agents selection
Fluconazole 16 (25.4%) 32 (38.1%) 0.104
Itraconazole 3 (4.8%) 11 (13.1%) 0.089
Voriconazolea 3 (4.8%) 4 (4.8%) 0.696
Antifungal therapy administered/changed after microbiological documentation 28 (44.4%) 36 (42.9%) 0.848
Agents selection
Fluconazole 4 (6.3%) 13 (15.5%) 0.087
Itraconazolea 6 (9.5%) 3 (3.6%) 0.253
Voriconazolea 4 (6.3%) 6 (7.1%) 0.887
Micafungina 3 (4.8%) 5 (6.0%) 0.958
Caspofungin 11 (17.5%) 9 (10.7%) 0.238
Overall
Triazoles usage 36 (57.1%) 66 (78.6%) 0.005
Echinocandins usage 14 (22.2%) 14 (16.7%) 0.396
Absence of antifungal therapies 16 (25.4%) 10 (11.9%) 0.034
Data are presented as n (%).
Antifungal agents were changed in 3 elderly patients and 6 younger patients.
aFisher’s exact test; Unspecified: chi-square test.
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therapy. As well, risk factors related to host characteristics
(e.g., underlying solid tumour, diabetes mellitus and chronic
renal failure) and hospital exposure (e.g., prior ICU stay,
mechanical ventilation, central venous catheters and ureth-
ral catheter placement) were identified more commonly in
elderly patients than younger patients. Thirdly, as a inde-
pendent risk factor for death in elderly, the absence of anti-
fungal therapies was more common than younger patients,
mostly because the patients or their guardians decided to
quit antifungal therapy.
The rapidly growing elderly population has specific
physiological characteristics, which makes it susceptible to
colonization and subsequent infection due to Candida spe-
cies [24]. Not surprisingly, in this study, the prevalence of
host-related risk factors, including solid tumour, diabetes
mellitus and chronic renal failure, was greater for elderly
than younger patients with candidemia. Cancer was a fre-
quent underlying disease in both younger and older patients,
but younger patients incurred a higher incidence of haem-
atological malignancies, whereas elderly patients were more
likely to present solid tumours, which is consistent with a
previous report [25].
Another main feature in the diagnosis of candidemia is
the evaluation of hospital-related risk factors [26]. Luzzati
et al. [27] reported that candidemia in elderly patients was
strongly associated with duration of total and peripheral
parenteral nutrition, other central vascular catheters
and glycopeptide antibiotics. Here, we identified more
healthcare-related factors, including prior ICU stay, mech-
anical ventilation and urethral catheter placement in
elderly patients. To decrease the incidence of candidemia
in elderly patients, methods aimed to reduce unnecessary
medical procedures should be encouraged whenever
feasible.
The elderly patients are particularly susceptible to vari-
ous infections and exposed to numerous antibiotic and
antifungal treatments. Exposure to antibiotics and antifun-
gal agents induces antifungal resistance and is an import-
ant cause of increased azoles-resistant Candida isolates
[28-30], which might explain our finding of high resist-
ance to azoles of non-C. albicans species in elderly pa-
tients. Non-C. albicans species such as C. glabrata, C.
parapsilosis and C. tropicalis are especially vulnerable to
acquiring resistance after a period of exposure to antifun-
gal agent [31]. The emergence of fluconazole resistance in
C. parapsilosis occurred after more than 10 years of flu-
conazole prophylaxis, which suggests that the use of flu-
conazole prophylaxis contributed to the emergence of C.
parapsilosis with decreased susceptibility among the
isolates responsible for bloodstream infections [32]. C.
glabrata may be intermediately resistant to all azoles, and
about 20% of strains develop resistance during therapy
and prophylaxis with fluconazole [13]; previous fluconazole
use is a significant risk factor for health care-associated
fluconazole-resistant C. glabrata [33]. Considering the low
resistance to caspofungin in the Candida isolates in elderly
patients, caspofungin might be a better alternative to treat
candidemia in this population.
In this study, elderly patients were more likely to ex-
perience septic shock and have poor outcomes than
Table 4 Laboratory data and outcomes of the elderly and younger patients with candidemia
Characteristics Elderly patients (≥65 years, n =63) Younger patients (16–60 years, n =84) p value
Laboratory data
Hemoglobin level (g/L) 86.9 ± 29.1 94.2 ± 30.9 0.148
Platelet count (×109/L) 163.4 ± 93.7 153.6 ± 117.1 0.586
Serum creatinine level (μmol/L) 112.0 ± 95.3 82.4 ± 65.6 0.027
Blood sugar level (mmol/L) 9.3 ± 5.1 6.7 ± 2.8 0.001
Serum sodium level (mmol/L) 138.6 ± 5.8 137.5 ± 5.4 0.238
Serum potassium level (mmol/L) 3.9 ± 1.0 3.8 ± 0.9 0.526
Total bilirubin level (μmol/L)b 16.3 (6.2-31.8) 13.9 (8.3-30.6) 0.271
High fever (>39°C)a 19 (30.2) 32 (38.1) 0.317
Removal of CVCa 14/32 (43.8%) 15/26 (57.7) 0.291
CVC-related candidemiaa 8 (12.7%) 10 (11.9%) 0.885
Concurrent bloodstream infectiona 8 (12.7) 14 (16.7) 0.505
APACHE II score 20.3 ± 8.1 14.6 ± 7.3 0.001
Age-adjusted APACHE II score 16.2 ± 7.7 13.9 ± 7.1 0.063
Septic shocka 27 (42.9) 24 (28.6) 0.072
30-day mortality ratea 20 (31.7) 14 (16.7) 0.032
Data are n (%), mean ± SD or median (IQR).
APACHE, Acute Physiology and Chronic Health Evaluation; CVC, central venous catheter.
aChi-square test; bMann-Whitney U test; Unspecified: Two-independent samples t-test.
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younger patients. The difference in outcome may be ex-
plained by higher severity of illness, as evidenced by in-
creased APACHE II score, a widely recognized scoring
system used to evaluate the severity of illness in critically ill
patients [23]. The APACHE II score is calculated from 12
routine physiological measurements, including age, mean
arterial pressure, heart rate, creatinine level, arterial pH,
serum potassium and sodium levels, hematocrit value,
Glasgow Coma Scale. However, after calculating an age-
adjusted APACHE II score, we found no significant differ-
ence in illness severity between elderly and younger groups.
Thus, advanced age rather than other indicators involved in
the APACHE II score was the crucial factor determining
the worse prognosis of elderly patients.
The elderly patients were more likely to not have anti-
fungal treatment than younger patients, and in agreement
with the previous report [34], the absence of antifungal
agents was independently associated with worse prognosis
in elderly. Therefore, prompt initiation of early antifungal
therapy is warranted in high-risk elderly patients. Elderly
patients or their guardians were likely to quit therapy
when the patient’s conditions worsened, mainly because of
lack of hope for the patient’s recovery, high hospitalization
expenses, or non-coverage of antifungal agents by medical
insurance. The poor care for elderly patients from family
members and society, as well as the lag in the medical in-
surance industry, are challenges to the health of geriatric
populations in China [35]. To decrease the high mortality
of elderly patients with candidemia, the absence of anti-
fungal therapy should be avoided by taking measures to
correct the above causes.
One of main points regarding candidemia is that delay-
ing antifungal treatment significantly increases mortality
[36]. Early treatment strategies, including prophylactic
Table 5 Univariate analysis of outcome in elderly patients with candidemia
Characteristics Non-survivors (n =20) Survivors (n =43) p value
Age ≥85 yearsa 4 (20.0) 5 (11.6) 0.619
Male sex 17 (85.0) 34 (79.1) 0.831
Solid tumora 8 (40.0) 7 (16.3) 0.082
Diabetes mellitus 8 (40.0) 16 (37.2) 0.832
Chronic renal failure 9 (45.0) 9 (20.9) 0.049
Prior immunosuppressive drugs 5 (25.0) 11 (25.6) 0.961
Severe hypoalbuminemia 8 (40.0) 5 (11.6) 0.040
Surgerya 5 (25.0) 9 (20.9) 0.971
ICU stay ≥5 days 9 (45.0) 10 (23.3) 0.080
Parental nutrition 7 (35.0) 13 (30.2) 0.705
Receipt of mechanical ventilation 14 (70.0) 13 (30.2) 0.003
CVC placement 9 (45.0) 23 (53.5) 0.530
CVC-related candidemiaa 1 (5.0) 7 (16.3) 0.398
CVC removala 1 (5.0) 13 (30.2) 0.055
Antifungal therapy administered before microbiological documentation 3 (15.0) 19 (44.2) 0.024
Prophylactic treatmenta 1 (5.0) 6 (14.0) 0.534
Empiric treatmenta 2 (10.0) 10 (23.3) 0.367
Antifungal therapy administered/changed after microbiological documentation 8 (40.0) 20 (46.5) 0.628
Triazoles usage 9 (45.0) 27 (62.8) 0.184
Echinocandins usage a 2 (10.0) 12 (27.9) 0.206
Absence of antifungal therapies 10 (50.0) 6 (14.0) 0.002
Platelet count ≤100 g/L × 109/L 7 (35.0) 5 (11.6) 0.028
Serum creatinine level ≥180 μmol/L 8 (40.0) 7 (16.3) 0.040
Total bilirubin level ≥30 μmol/L 9 (45.0) 7 (16.3) 0.015
Concurrent bacteraemia 6 (30.0) 2 (4.7) 0.016
APACHE II score ≥20 15 (75.0) 16 (37.2) 0.005
Septic shock 13 (65.0) 14 (32.6) 0.015
Data are n (%).
ICU, intensive care unit; CVC, central venous catheter; APACHE, Acute Physiology and Chronic Health Evaluation.
aFisher’s exact test; Unspecified: chi-square test.
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and empiric treatment is beneficial for patients with candi-
demia and decrease mortality [34,37]. Here, early antifungal
treatment administered before microbiology documenta-
tion was a protective factor for death and could improve
the outcome of elderly patients. However, we found no role
for prophylactic and empiric treatment in the outcome of
candidemia episodes: prophylactic and empiric treatment
was used more often, although not significantly, for survi-
vors than non-survivors, mostly because of the small num-
ber of older patients. A larger investigation with more cases
is warranted to disclose the potential role of different treat-
ment regimens on outcome in older population.
Our observations have several limitations. First the
retrospective design of the study limited our ability to ob-
tain exact variables such as prior antifungal exposures,
which could be important for the emergence of antifungal
resistance of non-C. albicans species. Second, compared
to results from previous reports [38-40], the removal rate
in the elderly patients was relatively low (43.8%), so the
real proportion of CVC-related candidemia as well as the
effect of CVC removal on prognosis might have been
underestimated. Considering that CVC retention has a
negative impact on outcome in patients with candidemia
[38-40], the awareness of the risk of CVC retention needs
to be strengthened in the management of candidemia in
Chinese hospitals. Third, we considered only the presence
or absence of risk factor exposure, not the duration of
exposure. Because the study was not designed to quantify
the length of exposure, this variable was not available
for analyses, and its associated bias could not be deter-
mined. Furthermore, some of our conclusions may not be
generalizable to other countries because of differences in an-
tifungal usage and the epidemiology of candidemia. Further
studies are necessary in different geographical areas.
Conclusion
In conclusion, the elderly patients account for a substantial
proportion of patients with candidemia and have higher
mortality than younger patients. Such patients are charac-
terized by certain host and hospital-related risk factors as
well as special pathogen resistance features. More aware-
ness of the burden of this disease is required and the ab-
sence of antifungal therapies should be avoided to improve
the prognoses of elderly patients with this severe infection.
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